安罗替尼治疗术后复发性颅内孤立性纤维瘤1例并文献复习

打开文本图片集

【中图分类号】 R651 【文献标志码】 B 【文章编号】1672-7770（2025）06-0697-04

Abstract：ObjectiveTo investigate the ficacy of anlotinib in the treatment of postoperativerecurrent intracranialsolitaryfibrous tumor（SFT）.MethodsApatientwithpostoperativerecurrentintracranialSFTtreated with anlotinibattheFirstAfiliatedHospitalofNanjing MedicalUniversityin2O22 was included.Theclinicalcharacteristics and targeted therapy eficacy wereanalyzed.ResultsThe patient underwent surgeryandradiotherapy for recurrence butexhibitedpoorresponse.Anlotinib treatment wasinitiatedtwomonths later.Folow-upMRIat12months demonstrated complete tumorregression.Atwo-yearfollow-uprevealedno recurence，andthepatient regained normal dailyfunction. ConclusionsAnlotinib shows promising efficacy in managing recurrent intracranial SFT.

KeyWords：solitary fibrous tumor（SFT）；hemangiopericytoma；anlotinib；tyrosine kinase inhibitor；recurenttumor

颅内孤立性纤维瘤（intracranial solitary fibrous tumor，ISFT）是中枢神经系统（centralnervoussystem，CNS）肿瘤中十分罕见的肿瘤类型，其发病率只占颅内肿瘤的不到 1% ，占脑膜瘤的 2%～4%[1] 。（剩余10690字）